Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02003924 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,401
- Enrollment target
NCT02003924 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,401 participants.
The verdict
NCT02003924, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,401 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
Interventions
- DRUG Placebo
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,401 participants |
| Start Date | 2013-10-31 |
| Est. Completion | 2025-11-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02003924
The ClinicalTrials.gov registry entry for NCT02003924 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02003924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02003924 about?
NCT02003924 is a clinical study titled "Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer". The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
What is the current status of trial NCT02003924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,401 participants. The study started on 2013-10-31. Estimated completion is 2025-11-28.
What interventions are being tested in trial NCT02003924?
The interventions under investigation include: Placebo (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02003924?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.